Sentences with phrase «trials on this biotechnology»

Not exact matches

Chengdu MedGenCell, a biotechnology company and a collaborator on the trial, will validate the cells to ensure that the correct genes are knocked out before the cells are re-introduced into the patients, says oncologist Lei Deng of West China Hospital, who is a member of Lu's team.

Earlier this month, Casey told a conference on biotechnology in London that he expects the forthcoming trials to be completed in a year's time.

The news followed closely on other disappointing results in the past couple of weeks from biotechnology companies such as Ribi Pharmaceuticals, which abandoned a trial of a melanoma treatment, and Rapligen, which made financial cutbacks.

This publication comes on the heels of a British clinical trial for wet AMD published last week in Nature Biotechnology.

In recent years, researchers have developed so - called «senolytic» drugs that wipe out senescent cells in aging mice and mouse models of age - related disease, exploiting the high dependence of these cells on specific biochemical survival pathways.9, 10 In these studies, senolytic drugs have restored exercise capacity9 and formation of new blood and immune precursor cells11 in aging mice to near youthful norms, and prevented or treated mouse models of diseases of aging like osteoarthritis, 12 fibrotic lung disease, 13 hair loss, 14 atherosclerosis, 15,16 and age - related diseases of the heart itself.9 UNITY Biotechnology is leading a growing charge toward the clinic, with human clinical trials expected to begin in 2019.

Having previously published data on a variety of experimental mAbs against AS species in animal models -LRB-[16,20]; possibly [21]-RRB-, Prothena's Dale Schenk presented new data on additional experimental antibodies at SENS Research Foundation's Rejuvenation Biotechnology 2014 conference, roughly contemporaneous to its publication, [22] along with information specific to the humanized candidate PRX002, which is now being advanced into clinical trials.

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Jul. 17, 2017 — Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically - defined diseases, today announced the initiation of the Company's PRECISION - HD program, which includes PRECISION - HD1 and PRECISION - HD2, the Company's two Phase 1b / 2a clinical trials evaluating WVE - 120101 and WVE - 120102, respectively, for patients with Huntington's disease (HD).